LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$3.19
−3.04%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.25
From 52W high−86.10%
Volume74034.00
Market cap$6.72M
P/E (TTM)—
P/S (TTM)34.6x
Div yield—
Key dataSep 18, 2026
Open
$3.25
From 52W high
−86.10%
Volume
74034.00
Market cap
$6.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
32.5
MomentumView details →
1D Return
−3.04%
YTD Return
−64.54%
SummaryUpdated May 1, 2026
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a Canadian biotechnology company founded in 2004 and headquartered in Kelowna, British Columbia. The company went public on NASDAQ in January 2021. Lexaria operates as a drug delivery technology company focused on developing and commercializing its proprietary DehydraTECH platform, which enhances the oral absorption of active pharmaceutical ingredients. The company maintains an in-house research laboratory and holds an intellectual property portfolio comprising 23 granted patents and approximately 50 pending patents worldwide.
Similar companies
Latest newsMore news →
Lexaria Bioscience Corp. completed an institutional financing that, together with an Australian tax refund, brought in a net $7.9 million.3d agoLexaria Bioscience Corp. announced definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, expecting gross proceeds of approximately $5.9 million, with closing expected on or about September 9, 2026.12d agoLexaria Bioscience Corp. received a cash rebate of AUD$3,666,611.98 (USD$2.6 million) from the Australian Tax Office, deposited into the account of its wholly-owned subsidiary Lexaria (AU) Pty Ltd.19d ago